A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: LY2835219
DRUG: Letrozole
DRUG: Anastrozole
DRUG: Tamoxifen
DRUG: Exemestane
DRUG: Everolimus
DRUG: Trastuzumab
DRUG: LY3023414
DRUG: Fulvestrant
DRUG: Pertuzumab
DRUG: Loperamide
DRUG: Endocrine therapy

Sponsor

Eli Lilly and Company